Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Oosting, Sjoukje Fvan der Veldt, Astrid A M
Fehrmann, Rudolf S N
GeurtsvanKessel, Corine H
van Binnendijk, Rob S
Dingemans, Anne-Marie C
Smit, Egbert F
Hiltermann, T Jeroen N
den Hartog, Gerco
Jalving, Mathilda
Westphal, Tatjana T
Bhattacharya, Arkajyoti
de Wilt, Faye
Boerma, Annemarie
van Zijl, Lisanne
Rimmelzwaan, Guus F
Kvistborg, Pia
van Els, Cecile A C M
Rots, Nynke Y
van Baarle, Debbie
Haanen, John B A G
de Vries, Elisabeth G E
Type
ArticleLanguage
en
Metadata
Show full item recordTitle
Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours.Published in
The Lancet. Oncology 2022; online ahead of printPMID
35483383ae974a485f413a2113503eed53cd6c53
10.1016/S1470-2045(22)00203-0
Scopus Count
Collections
Related articles
- mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial.
- Authors: Oosting SF, van der Veldt AAM, GeurtsvanKessel CH, Fehrmann RSN, van Binnendijk RS, Dingemans AC, Smit EF, Hiltermann TJN, den Hartog G, Jalving M, Westphal TT, Bhattacharya A, van der Heiden M, Rimmelzwaan GF, Kvistborg P, Blank CU, Koopmans MPG, Huckriede ALW, van Els CACM, Rots NY, van Baarle D, Haanen JBAG, de Vries EGE
- Issue date: 2021 Dec
- Impaired seroconversion after SARS-CoV-2 mRNA vaccines in patients with solid tumours receiving anticancer treatment.
- Authors: Amatu A, Pani A, Patelli G, Gagliardi OM, Loparco M, Piscazzi D, Cassingena A, Tosi F, Ghezzi S, Campisi D, Grifantini R, Abrignani S, Siena S, Scaglione F, Sartore-Bianchi A
- Issue date: 2022 Mar
- Influenza vaccination in adult patients with solid tumours treated with chemotherapy.
- Authors: Vollaard A, Schreuder I, Slok-Raijmakers L, Opstelten W, Rimmelzwaan G, Gelderblom H
- Issue date: 2017 May
- Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
- Authors: Flaxman A, Marchevsky NG, Jenkin D, Aboagye J, Aley PK, Angus B, Belij-Rammerstorfer S, Bibi S, Bittaye M, Cappuccini F, Cicconi P, Clutterbuck EA, Davies S, Dejnirattisai W, Dold C, Ewer KJ, Folegatti PM, Fowler J, Hill AVS, Kerridge S, Minassian AM, Mongkolsapaya J, Mujadidi YF, Plested E, Ramasamy MN, Robinson H, Sanders H, Sheehan E, Smith H, Snape MD, Song R, Woods D, Screaton G, Gilbert SC, Voysey M, Pollard AJ, Lambe T, Oxford COVID Vaccine Trial group.
- Issue date: 2021 Sep 11
- Methotrexate Hampers Immunogenicity to BNT162b2 mRNA COVID-19 Vaccine in Immune-Mediated Inflammatory Disease.
- Authors: Haberman RH, Herati RS, Simon D, Samanovic M, Blank RB, Tuen M, Koralov SB, Atreya R, Tascilar K, Allen JR, Castillo R, Cornelius AR, Rackoff P, Solomon G, Adhikari S, Azar N, Rosenthal P, Izmirly P, Samuels J, Golden B, Reddy S, Neurath M, Abramson SB, Schett G, Mulligan MJ, Scher JU
- Issue date: 2021 May 12